Drug-induced proarrhythmia and use of QTc-prolonging agents: Clues for clinicians

Heart Rhythm

Volumn 2, Issue 11 SUPPL. 2, 2005, Pages S1-

  Heist, E Kevin ^a   Ruskin, Jeremy N ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Arrhythmia; Clinical practice; Drug; QT interval; QTc interval; Torsades de pointes

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTICONVULSIVE AGENT; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; ANTIMIGRAINE AGENT; ASTEMIZOLE; CALCIUM CHANNEL BLOCKING AGENT; CHLORAL HYDRATE; CISAPRIDE; DIURETIC AGENT; DOFETILIDE; DOXEPIN; DROPERIDOL; GREPAFLOXACIN; IBUTILIDE; KETOCONAZOLE; LITHIUM SALT; MOXIFLOXACIN; OCTREOTIDE; PSYCHOTROPIC AGENT; QUINIDINE; SALMETEROL; SOTALOL; TACROLIMUS; TAMOXIFEN; TERFENADINE; THIORIDAZINE; TIZANIDINE; UNINDEXED DRUG; ZIPRASIDONE;

ACCURACY; AGE; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DISEASE PREDISPOSITION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG EXPOSURE; DRUG FATALITY; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; GENDER; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART PROARRHYTHMIA; HEART REPOLARIZATION; HIGH RISK PATIENT; HUMAN; PATHOGENESIS; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; QT PROLONGATION; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SUDDEN DEATH; TORSADE DES POINTES;

EID: 27744580767     PISSN: 15475271     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hrthm.2005.07.017     Document Type: Article

References (37)

1. F. De Ponti E. Poluzzi N. Montanaro J. Ferguson QTc and psychotropic drugs Lancet 356 2000 75-76
2. Curtis L.H. Østbye T. Sendersky V. Hutchison S. Allen LaPointe N.M. Al-Khatib S.M. Usdin Yasuda S. Dans P.E. Wright A. Califf R.M. Woosley R.L. Schulman K.A. Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. Am J Med 2003;114:135-141.
3. Selzer A. Wray H.W. Quinidine syncope, paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias. Circulation 1964;30:17-26.
4. D.M. Roden Drug-induced prolongation of the QT interval N Engl J Med 350 2004 1013-1022
5. A. Jervell F. Lange-Nielsen Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval, and sudden death Am Heart J 54 1957 59-68
6. O.C. Ward A new familial cardiac syndrome in children J Isr Med Assoc 54 1964 103-106
7. C.M. Pratt R.P. Hertz B.E. Ellis S.P. Crowell W. Louv L. Moye Risk of developing life-threatening ventricular arrhythmia associated with terfenadine in comparison with over-the-counter antihistamines, ibuprofen and clemastine Am J Cardiol 73 1994346-352
8. J.P. Hanrahan P.W. Choo W. Carlson D. Greineder G.A. Faich R. Platt Terfenadine-associated ventricular arrhythmias and QTc interval prolongation. A retrospective cohort comparison with other antihistamines among members of a health maintenance organization Ann Epidemiol 5 1995 201-209
9. L.M. DuBuske Second-generation antihistamines: The risk of ventricular arrhythmias Clin Ther 21 1999 281-295
10. M. Jurima-Romet K. Crawford T. Cyr T. Inaba Terfenadine metabolism in human liver Drug Metab Dispos 22 1994 849-857
11. P.K. Honig D.C. Wortham K. Zamani D.P. Conner J. Mullin L.R. Cantilena Terfenadine-ketoconazole interaction JAMA 269 1993 1513-1518
12. R.E. Benton P.K. Honig K. Zamani L.R. Cantilena R.L. Woosley Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram Clin Pharmacol Ther 59 1996 383-388
13. R.R. Fenichel M. Malik C. Antzelevitch M. Sanguinetti D.M. Roden S.G. Priori J.N. Ruskin R.J. Lipicky L.R. Cantilena Drug-induced torsades de pointes and implications for drug development J Cardiovasc Electrophysiol 15 2004 475-495
14. C.H. Luo Y. Rudy A dynamic model of the cardiac ventricular action potential. I. Simulations of ionic currents and concentration changes Circ Res 74 1994 1071-1096
15. C.E. Clancy R.S. Kass Inherited and acquired vulnerability to ventricular arrhythmias cardiac Na+ and K+ channels Physiol Rev 85 2005 33-47
16. M.T. Keating M.C. Sanguinetti Molecular and cellular mechanisms of cardiac arrhythmias Cell 104 2001 569-580
17. J.S. Cordes Z. Sun D.B. Lloyd J.A. Bradley A.C. Opsahl M.W. Tengowski X. Chen J. Zhou Pentamidine reduces hERG expression to prolong the QT interval Br J Pharmacol 145 2005 15-23
18. J. Kang X.L. Chen H. Wang J. Ji H. Cheng J. Incardona W. Reynolds F. Viviani M. Tabart D. Rampe Discovery of a small molecule activator of the human ether-a-go-go-related gene (HERG) cardiac K+ channel Mol Pharmacol 67 2005 827-836
19. T. Yang D. Snyders D.M. Roden Drug block of I(kr): Model systems and relevance to human arrhythmias J Cardiovasc Pharmacol 38 2001 737-744
20. R. Lazzara Amiodarone and torsade de pointes Ann Intern Med 111 1989 549-551
21. J.M. van Opstal M. Schoenmakers S.C. Verduyn S.H. de Groot J.D. Leunissen F.F. van Der Hulst M.M. Molenschot H.J. Wellens M.A. Vos Chronic amiodarone evokes no torsade de pointes arrhythmias despite QT lengthening in an animal model of acquired long-QT syndrome Circulation 104 2001 2722-2727
22. P. Milberg L. Eckardt H.J. Bruns J. Biertz S. Ramtin N. Reinsch D. Fleischer P. Kirchhof L. Fabritz G. Breithardt W. Haverkamp Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: Fast phase 3 repolarization prevents early after depolarizations and torsade de pointes J Pharmacol Exp Ther 303 2002 218-225
23. L. Belardinelli C. Antzelevitch M.A. Vos Assessing predictors of drug-induced torsade de pointes Trends Pharmacol Sci 24 2003 619-625
24. C. Antzelevitch W. Shimizu Cellular mechanisms underlying the long QT syndrome Curr Opin Cardiol 17 2002 43-51
25. D.M. Roden Taking the "idio" out of "idiosyncratic": predicting torsades de pointes Pacing Clin Electrophysiol 21 1998 1029-1034
26. R.R. Makkar B.S. Fromm R.T. Steinman M.D. Meissner M.H. Lehmann Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs JAMA 270 1993 2590-2597
27. M.M. Bednar E.P. Harrigan J.N. Ruskin Torsades de pointes associated with nonantiarrhythmic drugs and observations on gender and QTc Am J Cardiol 89 2002 1316-1319
28. I. Splawski K.W. Timothy M. Tateyama C.E. Clancy A. Malhotra A.H. Beggs F.P. Cappuccio G.A. Sagnella R.S. Kass M.T. Keating Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia Science 297 2002 1333-1336
29. S.G. Priori C. Napolitano Genetic defects of cardiac ion channels. The hidden substrate for torsades de pointes Cardiovasc Drugs Ther 16 2002 89-92
30. T. Yang D.M. Roden Extracellular potassium modulation of drug block of Ikr implications for torsades de pointes and reverse use-dependence Circulation 93 1996 407-411
31. W. Haverkamp G. Breithardt A.J. Camm M.J. Janse M.R. Rosen C. Antzelevich D. Escande M. Franz M. Malik A. Moss R. Shah The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology Eur Heart J 21 2000 1216-1231
32. M.H. Lehmann S. Hardy D. Archibald B. Quart D.J. MacNeil Sex difference in risk of torsade de pointes with d,l-sotalol Circulation 94 1996 2535-2541
33. M. Møller C.T. Torp-Pedersen L. Køber The Danish Investigators of Arrhythmia and Mortality on Dofetilide (DIAMOND) Study Group Dofetilide in patients with congestive heart failure and left ventricular dysfunction: Safety aspects and effect on atrial fibrillation Congest Heart Fail 7 2001 146-150
34. A. Farkas I. Leprán J.G. Papp Proarrhythmic effects of intravenous quinidine, amiodarone, D-sotalol, and almokalant in the anesthetized rabbit model of torsade de pointes J Cardiovasc Pharmacol 39 2002 287-297
35. R.L. Woosley Drug labeling revisions-guaranteed to fail? JAMA 284 2000 3047-3049
36. S.T. McMullin R.M. Reichley L.A. Watson S.A. Steib M.E. Frisse T.C. Bailey Impact of a Web-based clinical information system on cisapride drug interactions and patient safety Arch Intern Med 159 1999 2077-2082
37. D. Zeltser D. Justo A. Halkin V. Prokhorov K. Heller S. Viskin Torsade de pointes due to noncardiac drugs most patients have easily identifiable risk factors Medicine (Baltimore) 82 2003 282-290